The future of incretin-based therapy: novel avenues-novel targets.
(2011) In Diabetes, Obesity and Metabolism 13 Suppl 1. p.158-166- Abstract
- Incretin-based therapy for type 2 diabetes is based on the antidiabetic effects of glucagon-like peptide-1 (GLP-1) and instituted by GLP-1 receptor agonists and dipeptidyl peptidase-4 inhibitors targeting the key islet defects of the disease. The treatment is clinically efficient and safe, and associated with a low risk of adverse events. It can be used both in early and late stages of the disease and both as monotherapy and add-on to other therapies. Current research on the future of incretin-based therapy focuses on optimizing its place in diabetes treatment and examines its potential in type 1 diabetes, in subjects with obesity without type 2 diabetes and in cardiovascular and neurodegenerative disorders. Other studies aim at prolonging... (More)
- Incretin-based therapy for type 2 diabetes is based on the antidiabetic effects of glucagon-like peptide-1 (GLP-1) and instituted by GLP-1 receptor agonists and dipeptidyl peptidase-4 inhibitors targeting the key islet defects of the disease. The treatment is clinically efficient and safe, and associated with a low risk of adverse events. It can be used both in early and late stages of the disease and both as monotherapy and add-on to other therapies. Current research on the future of incretin-based therapy focuses on optimizing its place in diabetes treatment and examines its potential in type 1 diabetes, in subjects with obesity without type 2 diabetes and in cardiovascular and neurodegenerative disorders. Other studies aim at prolonging the duration of action of the GLP-1 receptor agonists to allow weekly administration, and to develop orally GLP-1 receptor agonists. Furthermore, other investigators focus on stimulation of GLP-1 secretion by activating GLP-1-producing L-cells or using gene therapy. Finally, also other gastro-entero-pancreatic bioactive peptides are potential targets for drug development as are synthetic peptides engineered as co-agonists stimulating more than one receptor. We can therefore expect a dynamic development within this field in the coming years. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/2151087
- author
- Ahrén, Bo LU
- organization
- publishing date
- 2011
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Diabetes, Obesity and Metabolism
- volume
- 13 Suppl 1
- pages
- 158 - 166
- publisher
- Wiley-Blackwell
- external identifiers
-
- wos:000295344400022
- pmid:21824270
- scopus:79961175481
- pmid:21824270
- ISSN
- 1462-8902
- DOI
- 10.1111/j.1463-1326.2011.01457.x
- language
- English
- LU publication?
- yes
- id
- d911b58f-7efb-49db-9f52-8a1060ccc8ed (old id 2151087)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/21824270?dopt=Abstract
- date added to LUP
- 2016-04-04 07:34:53
- date last changed
- 2024-02-10 20:20:33
@article{d911b58f-7efb-49db-9f52-8a1060ccc8ed,
abstract = {{Incretin-based therapy for type 2 diabetes is based on the antidiabetic effects of glucagon-like peptide-1 (GLP-1) and instituted by GLP-1 receptor agonists and dipeptidyl peptidase-4 inhibitors targeting the key islet defects of the disease. The treatment is clinically efficient and safe, and associated with a low risk of adverse events. It can be used both in early and late stages of the disease and both as monotherapy and add-on to other therapies. Current research on the future of incretin-based therapy focuses on optimizing its place in diabetes treatment and examines its potential in type 1 diabetes, in subjects with obesity without type 2 diabetes and in cardiovascular and neurodegenerative disorders. Other studies aim at prolonging the duration of action of the GLP-1 receptor agonists to allow weekly administration, and to develop orally GLP-1 receptor agonists. Furthermore, other investigators focus on stimulation of GLP-1 secretion by activating GLP-1-producing L-cells or using gene therapy. Finally, also other gastro-entero-pancreatic bioactive peptides are potential targets for drug development as are synthetic peptides engineered as co-agonists stimulating more than one receptor. We can therefore expect a dynamic development within this field in the coming years.}},
author = {{Ahrén, Bo}},
issn = {{1462-8902}},
language = {{eng}},
pages = {{158--166}},
publisher = {{Wiley-Blackwell}},
series = {{Diabetes, Obesity and Metabolism}},
title = {{The future of incretin-based therapy: novel avenues-novel targets.}},
url = {{http://dx.doi.org/10.1111/j.1463-1326.2011.01457.x}},
doi = {{10.1111/j.1463-1326.2011.01457.x}},
volume = {{13 Suppl 1}},
year = {{2011}},
}